Summary & Overview
CPT 89264: Sperm Identification from Testis Tissue, Laboratory Procedure
CPT code 89264 represents the laboratory procedure for sperm identification from testis tissue, either fresh or cryopreserved. This service is integral to reproductive medicine, especially in the diagnosis and management of male infertility. The procedure is typically performed in a laboratory environment and is essential for patients undergoing fertility evaluation or treatment, including those with conditions such as azoospermia or oligospermia.
Major national payers covering this code include Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare. The publication provides a comprehensive overview of payer coverage, clinical context, and policy updates relevant to this procedure. Readers will gain insights into coding benchmarks, common modifiers, associated provider taxonomies, and related diagnoses. The analysis also highlights related CPT codes and the typical clinical scenarios in which 89264 is utilized.
This summary is designed for healthcare professionals, billing specialists, and policy analysts seeking up-to-date information on laboratory-based reproductive procedures. The content addresses the importance of accurate coding, payer policies, and clinical relevance in the context of male infertility and fertility testing.
CPT Code Overview
CPT code 89264 is used to report the identification of sperm from testis tissue, whether the tissue is fresh or cryopreserved. This procedure is a key component of reproductive medicine, particularly in the evaluation and management of male infertility. The service is typically performed in a laboratory setting (Place of Service 81), where specialized techniques are used to isolate and identify sperm cells from testicular samples. This process supports fertility treatment options and assists clinicians in determining the most appropriate interventions for patients seeking reproductive assistance.
Clinical & Coding Specifications
Clinical Context
A male patient presents to a reproductive endocrinology clinic with a history of infertility. After initial evaluation, the patient is found to have azoospermia, meaning no sperm is present in the ejaculate. To further assess fertility potential, a testicular biopsy is performed. The fresh or cryopreserved testis tissue is sent to a laboratory (Place of Service 81) for sperm identification using procedure 89264. The laboratory analyzes the tissue to determine if viable sperm are present, which may be used for assisted reproductive techniques such as IVF or ICSI.
Coding Specifications
-
Modifiers:
- Modifier
26: Used when reporting only the professional component of the laboratory service (interpretation of results). - Modifier
TC: Used when reporting only the technical component (performance of the laboratory procedure).
- Modifier
-
Provider Taxonomies:
| Taxonomy Code | Specialty Name |
|---|---|
207VE0102X | Reproductive Endocrinology Physician |
207V00000X | Obstetrics & Gynecology Physician |
207U00000X | Clinical Laboratory Director, Non-physician |
These specialties are typically involved in ordering, performing, or interpreting the sperm identification procedure.
Related Diagnoses
-
N46.9: Male infertility, unspecified- Used when the cause of male infertility is not specifically identified. Relevant for patients undergoing sperm identification to determine fertility status.
-
N46.01: Azoospermia- Indicates absence of sperm in the ejaculate. Directly relevant to the use of
89264for identifying sperm in testicular tissue.
- Indicates absence of sperm in the ejaculate. Directly relevant to the use of
-
N46.11: Oligospermia- Indicates low sperm count. Sperm identification from testis tissue may be performed to assess sperm availability for assisted reproduction.
-
N46.8: Other male infertility- Used for other specified causes of male infertility. Sperm identification may be part of the diagnostic workup.
-
Z31.41: Encounter for fertility testing- Used when the patient is undergoing evaluation for fertility, including procedures like sperm identification from testis tissue.
Related CPT Codes
-
89257: Sperm identification from aspiration (other than seminal fluid)- Used when sperm identification is performed on tissue obtained by aspiration rather than biopsy. May be an alternative to
89264depending on the method of tissue collection.
- Used when sperm identification is performed on tissue obtained by aspiration rather than biopsy. May be an alternative to
-
89335: Cryopreservation, reproductive tissue, testicular- Used for the cryopreservation of testicular tissue, which may be performed in conjunction with
89264if sperm are identified and tissue is to be stored for future use.
- Used for the cryopreservation of testicular tissue, which may be performed in conjunction with
89257 and 89335 are commonly used in workflows involving male infertility evaluation and assisted reproductive procedures. 89257 may be an alternative to 89264, while 89335 is often used together with 89264 when cryopreservation is indicated.
National Reimbursement Benchmarks
National mean rates for CPT code 89264 show that UnitedHealth Group has the highest average reimbursement at $307.28, while Cigna is the lowest among commercial payers at $105.83. The BUCA mean rate, representing the average across major commercial payers, is $180.26. Medicare data is not available in the input, so no comparison can be made.
Rate dispersion varies significantly across payers. UnitedHealth Group exhibits the widest spread, with a difference of $277.00 between the 75th and 25th percentiles, indicating substantial variability in contracted rates. In contrast, Aetna has a tighter range of $47.67, suggesting more consistent reimbursement levels. Blue Cross Blue Shield and Cigna also show moderate dispersion, with ranges of $156.12 and $73.00, respectively.
The table and chart below present a detailed breakdown of national benchmarks for each payer.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.